Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos(University of Liverpool), Daniel H. Palmer(University of Liverpool), Paula Ghaneh(University of Liverpool), Eftychia Eirini Psarelli(University of Liverpool), Juan W. Valle(University of Manchester), Christopher Halloran(University of Liverpool), Olusola Olusesan Faluyi(Clatterbridge Cancer Centre NHS Foundation Trust), Derek O’Reilly(Manchester Royal Infirmary), David Cunningham(Royal Marsden Hospital), Jonathan Wadsley(Weston Park Cancer Centre), Suzanne Darby(Weston Park Cancer Centre), Tim Meyer(The Royal Free Hospital), Roopinder Gillmore(The Royal Free Hospital), Alan Anthoney(St James's University Hospital), Pehr Lind(Karolinska Institutet), Bengt Glimelius(Uppsala University), Stephen Falk(At Bristol), Jakob R. Izbicki(Universität Hamburg), Gary Middleton(Royal Surrey County Hospital), Sebastian Cummins(Royal Surrey County Hospital), Paul J. Ross(Guy's Hospital), Harpreet Wasan(Hammersmith Hospital), Alec McDonald(Beatson West of Scotland Cancer Centre), Tom Crosby(Velindre NHS Trust), Yuk Ting(Queen Elizabeth Hospital Birmingham), Kinnari Patel(Churchill Hospital), David Sherriff(Derriford Hospital), Rubin Soomal(Ipswich Hospital), David Borg(Skåne University Hospital), Sharmila Sothi(University Hospital Coventry), Pascal Hammel(Hôpital Beaujon), Thilo Hackert(Heidelberg University), Richard Jackson(University of Liverpool), Markus W. Büchler(Heidelberg University)
The Lancet
January 24, 2017
Cited by 1,921Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis